• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成骨细胞在磷酸盐代谢中的作用。

Roles of osteocytes in phosphate metabolism.

机构信息

Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Izumi, Japan.

出版信息

Front Endocrinol (Lausanne). 2022 Jul 15;13:967774. doi: 10.3389/fendo.2022.967774. eCollection 2022.

DOI:10.3389/fendo.2022.967774
PMID:35909535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9334555/
Abstract

Osteocytes are dendritic cells in the mineralized bone matrix that descend from osteoblasts. They play critical roles in controlling bone mass through the production of sclerostin, an inhibitor of bone formation, and receptor activator of nuclear factor κ B ligand, an inducer of osteoblastic bone resorption. Osteocytes also govern phosphate homeostasis through the production of fibroblast growth factor 23 (FGF23), which lowers serum phosphate levels by increasing renal phosphate excretion and reducing the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)D), an active metabolite of vitamin D. The production of FGF23 in osteocytes is regulated by various local and systemic factors. (), (), and function as local negative regulators of FGF23 production in osteocytes, and their inactivation causes the overproduction of FGF23 and hypophosphatemia. Sclerostin has been suggested to regulate the production of FGF23, which may link the two functions of osteocytes, namely, the control of bone mass and regulation of phosphate homeostasis. Systemic regulators of FGF23 production include 1,25(OH)D, phosphate, parathyroid hormone, insulin, iron, and inflammation. Therefore, the regulation of FGF23 in osteocytes is complex and multifactorial. Recent mouse studies have suggested that decreases in serum phosphate levels from youth to adulthood are caused by growth-related increases in FGF23 production by osteocytes, which are associated with the down-regulation of and .

摘要

成骨细胞是矿化骨基质中的树突状细胞,起源于成骨细胞。它们通过产生骨硬化蛋白(一种骨形成抑制剂)和核因子 κ B 配体受体激活剂(一种诱导成骨细胞骨吸收的物质),在控制骨量方面发挥着关键作用。成骨细胞还通过产生成纤维细胞生长因子 23(FGF23)来调节磷酸盐稳态,通过增加肾脏磷酸盐排泄和减少 1,25-二羟基维生素 D(维生素 D 的活性代谢物)的合成来降低血清磷酸盐水平。成骨细胞中 FGF23 的产生受多种局部和全身因素的调节。()、()和()作为成骨细胞中 FGF23 产生的局部负调节剂,其失活导致 FGF23 的过度产生和低磷酸盐血症。骨硬化蛋白被认为调节 FGF23 的产生,这可能将成骨细胞的两个功能(即控制骨量和调节磷酸盐稳态)联系起来。FGF23 产生的系统性调节剂包括 1,25-二羟基维生素 D、磷酸盐、甲状旁腺激素、胰岛素、铁和炎症。因此,成骨细胞中 FGF23 的调节是复杂的和多因素的。最近的小鼠研究表明,从青少年到成年期血清磷酸盐水平的降低是由于成骨细胞中 FGF23 产生的与生长相关的增加引起的,这与 和 的下调有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8506/9334555/69ee1ab07a00/fendo-13-967774-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8506/9334555/6b16dc927555/fendo-13-967774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8506/9334555/69ee1ab07a00/fendo-13-967774-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8506/9334555/6b16dc927555/fendo-13-967774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8506/9334555/69ee1ab07a00/fendo-13-967774-g002.jpg

相似文献

1
Roles of osteocytes in phosphate metabolism.成骨细胞在磷酸盐代谢中的作用。
Front Endocrinol (Lausanne). 2022 Jul 15;13:967774. doi: 10.3389/fendo.2022.967774. eCollection 2022.
2
Osteocytes and the pathogenesis of hypophosphatemic rickets.成骨细胞与低血磷性佝偻病的发病机制。
Front Endocrinol (Lausanne). 2022 Sep 29;13:1005189. doi: 10.3389/fendo.2022.1005189. eCollection 2022.
3
Osteocyte-specific deletion of Fgfr1 suppresses FGF23.成骨细胞特异性缺失Fgfr1可抑制FGF23。
PLoS One. 2014 Aug 4;9(8):e104154. doi: 10.1371/journal.pone.0104154. eCollection 2014.
4
Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23.骨矿化是由局部和全身来源的分子因子的信号串扰调节的:成纤维细胞生长因子 23 的作用。
Biofactors. 2014 Nov-Dec;40(6):555-68. doi: 10.1002/biof.1186. Epub 2014 Oct 29.
5
Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.在Hyp小鼠中,内在骨细胞异常和全身因素在FGF23调节及骨矿化中的不同作用。
Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1636-44. doi: 10.1152/ajpendo.00396.2007. Epub 2007 Sep 11.
6
Growth-related skeletal changes and alterations in phosphate metabolism.生长相关的骨骼变化和磷酸盐代谢改变。
Bone. 2022 Aug;161:116430. doi: 10.1016/j.bone.2022.116430. Epub 2022 May 13.
7
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.成纤维细胞生长因子23在调节全身磷酸盐稳态和细胞外基质矿化的骨-肾轴中的新作用。
Curr Opin Nephrol Hypertens. 2007 Jul;16(4):329-35. doi: 10.1097/MNH.0b013e3281ca6ffd.
8
Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.骨硬化蛋白抗体可改善成年 Hyp 小鼠的磷酸盐代谢激素、成骨速率和骨量。
Bone. 2022 Jan;154:116201. doi: 10.1016/j.bone.2021.116201. Epub 2021 Sep 16.
9
Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.骨蛋白 PHEX 和 DMP1 通过涉及成纤维细胞生长因子受体 (FGFR) 信号通路的共同途径调节骨细胞中成纤维细胞生长因子 Fgf23 的表达。
FASEB J. 2011 Aug;25(8):2551-62. doi: 10.1096/fj.10-177816. Epub 2011 Apr 20.
10
Pathogenic role of Fgf23 in Hyp mice.成纤维细胞生长因子23(Fgf23)在Hyp小鼠中的致病作用。
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E38-49. doi: 10.1152/ajpendo.00008.2006. Epub 2006 Jan 31.

引用本文的文献

1
COX2-independent and COX2-dependent effects of naproxen on bone quality, osteocytes, and fatigue fracture healing in male and female mice.萘普生对雄性和雌性小鼠骨质量、骨细胞及疲劳性骨折愈合的COX2非依赖性和COX2依赖性作用。
bioRxiv. 2025 Aug 25:2025.08.20.669939. doi: 10.1101/2025.08.20.669939.
2
Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement.评估羧基麦芽糖铁导致低磷血症的风险及推荐的管理方法:一项共识声明。
J Clin Med. 2025 Jul 9;14(14):4861. doi: 10.3390/jcm14144861.
3
Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded.

本文引用的文献

1
Growth-related skeletal changes and alterations in phosphate metabolism.生长相关的骨骼变化和磷酸盐代谢改变。
Bone. 2022 Aug;161:116430. doi: 10.1016/j.bone.2022.116430. Epub 2022 May 13.
2
The regulation of FGF23 under physiological and pathophysiological conditions.成纤维细胞生长因子 23 在生理和病理生理条件下的调节。
Pflugers Arch. 2022 Mar;474(3):281-292. doi: 10.1007/s00424-022-02668-w. Epub 2022 Jan 27.
3
Regulation of FGF23: Beyond Bone.FGF23 的调控:超越骨骼。
磷酸盐在生理和病理矿化中的作用:重要却常被忽视。
MedComm (2020). 2025 Jul 13;6(7):e70298. doi: 10.1002/mco2.70298. eCollection 2025 Jul.
4
Impact of Somatic Development and Course of Osteogenesis Imperfecta on FGF23 Levels in Children.成骨不全症的躯体发育及病程对儿童成纤维细胞生长因子23水平的影响
Int J Mol Sci. 2025 Jun 23;26(13):6007. doi: 10.3390/ijms26136007.
5
Development of animal models with chronic kidney disease-mineral and bone disorder based on clinical characteristics and pathogenesis.基于临床特征和发病机制的慢性肾脏病-矿物质和骨异常动物模型的建立
Front Endocrinol (Lausanne). 2025 Mar 25;16:1549562. doi: 10.3389/fendo.2025.1549562. eCollection 2025.
6
Wnt7b overexpression in osteoblasts stimulates bone formation and reduces obesity in mice on a high-fat diet.成骨细胞中Wnt7b的过表达可刺激骨形成,并减轻高脂饮食小鼠的肥胖。
JBMR Plus. 2024 Sep 23;8(11):ziae122. doi: 10.1093/jbmrpl/ziae122. eCollection 2024 Nov.
7
The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies.硬化蛋白与肾移植矿物质骨病的关系:一个充满争议的分子
Calcif Tissue Int. 2024 Oct;115(4):339-361. doi: 10.1007/s00223-024-01261-w. Epub 2024 Jul 30.
8
Prevalence and risk factors predisposing low bone mineral density in patients with thalassemia.地中海贫血患者低骨密度的患病率及相关危险因素。
Front Endocrinol (Lausanne). 2024 Jun 24;15:1393865. doi: 10.3389/fendo.2024.1393865. eCollection 2024.
9
X-linked hypophosphatemic rickets: from diagnosis to management.X连锁低磷性佝偻病:从诊断到治疗
Clin Exp Pediatr. 2024 Jan;67(1):17-25. doi: 10.3345/cep.2022.01459. Epub 2023 Jun 14.
10
Mature primary human osteocytes in mini organotypic cultures secrete FGF23 and PTH1-34-regulated sclerostin.原代培养的成熟人成骨细胞在微器官型培养中分泌 FGF23 和 PTH1-34 调节的骨硬化蛋白。
Front Endocrinol (Lausanne). 2023 May 8;14:1167734. doi: 10.3389/fendo.2023.1167734. eCollection 2023.
Curr Osteoporos Rep. 2021 Dec;19(6):563-573. doi: 10.1007/s11914-021-00703-w. Epub 2021 Nov 10.
4
The osteocyte as a signaling cell.成骨细胞作为一种信号细胞。
Physiol Rev. 2022 Jan 1;102(1):379-410. doi: 10.1152/physrev.00043.2020. Epub 2021 Aug 2.
5
Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease.脂质运载蛋白2刺激慢性肾病中骨成纤维细胞生长因子23的产生。
Bone Res. 2021 Aug 2;9(1):35. doi: 10.1038/s41413-021-00154-0.
6
Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23.骨硬化蛋白直接刺激骨细胞合成成纤维细胞生长因子 23。
Calcif Tissue Int. 2021 Jul;109(1):66-76. doi: 10.1007/s00223-021-00823-6. Epub 2021 Feb 22.
7
Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25-Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor-23.维生素D受体介导众多依赖其1,25-二羟维生素D配体的生物学作用:通过诱导Klotho和成纤维细胞生长因子-23揭示的不同调控主题。
JBMR Plus. 2020 Dec 3;5(1):e10432. doi: 10.1002/jbm4.10432. eCollection 2021 Jan.
8
Lack of PTEN in osteocytes increases circulating phosphate concentrations by decreasing intact fibroblast growth factor 23 levels.成骨细胞中缺乏 PTEN 会通过降低完整成纤维细胞生长因子 23 水平来增加循环磷酸盐浓度。
Sci Rep. 2020 Dec 9;10(1):21501. doi: 10.1038/s41598-020-78692-6.
9
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.成纤维细胞生长因子 23 相关低磷血症性佝偻病/骨软化症:诊断与新治疗。
J Mol Endocrinol. 2021 Feb;66(2):R57-R65. doi: 10.1530/JME-20-0089.
10
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.利塞膦酸钠对高转换型肾性骨营养不良大鼠模型的骨骼和矿物质代谢的影响。
J Bone Miner Metab. 2020 Jul;38(4):501-510. doi: 10.1007/s00774-020-01095-0. Epub 2020 Mar 5.